longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Zai Lab Grants New Share Options and RSUs Under 2024 Equity Plan

Tip Ranks
Jul 3, 2026 at 08:38 AM
LongbridgeAII'm LongbridgeAI, I can summarize articles.

Zai Lab (HK:9688) granted new share options and restricted stock units under its 2024 Equity Incentive Plan. Options for 20,000 shares were issued to one employee, while RSUs for 848,930 shares were granted to four recipients, including CEO Dr. Samantha Du. The awards vest over multiple years with no performance targets, aiming to align interests and retain key personnel. Analysts maintain a Hold rating with an HK$18.00 price target.

Zai Lab Ltd ( (HK:9688) ) has issued an announcement.

Zai Lab Limited has granted new share options and restricted share units under its 2024 Equity Incentive Plan, issuing options over 20,000 shares to one employee and RSUs over 848,930 shares to four grantees, including Chairperson and CEO Dr. Samantha Du. The awards, which vest over multiple years and carry no performance targets or clawback mechanisms, underscore the company’s reliance on long-term equity incentives to align management and staff with shareholder interests and support retention of key personnel.

The stock options are priced at US$19.12 per ADS with a ten-year term, vesting in four equal annual tranches contingent on continued employment, while the RSUs are granted at no purchase price and similarly structured to promote long-term commitment. By confirming that these terms are consistent with market practice and its established policies, Zai Lab signals a continued emphasis on competitive remuneration, which may influence its cost structure but is intended to strengthen leadership stability and support execution of its growth strategy.

The most recent analyst rating on (HK:9688) stock is a Hold
with a HK$18.00 price target.
To see the full list of analyst forecasts on Zai Lab Ltd stock,
see the HK:9688 Stock Forecast page.

More about Zai Lab Ltd

Zai Lab Limited is a biopharmaceutical company listed in Hong Kong and the U.S., focused on developing and commercializing innovative medicines. The company uses equity-based incentives as part of its compensation strategy to attract and retain key talent in a competitive global life sciences market.

Average Trading Volume: 12,621,007

Technical Sentiment Signal: Sell

Current Market Cap: HK$17.02B

Login to unlock1,266characters for free

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

Related Stocks

ZAI LAB

ZAI LAB

HK09688

+0.26%

Zai Lab

Zai Lab

USZLAB

+1.82%

LongbridgeAI